Payden & Rygel’s CME Group CME Stock Holding History

Payden & Rygel’s Portfolio CME Stock Details CME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,600	Closed	-$574K	–	127
2024 Q3	$574K	Sell	2,600 -29,700	-92%	-$6.15M	0.04%	94
2024 Q2	$6.35M	Buy	32,300 +29,700	+1,142%	+$6.14M	0.51%	68
2024 Q1	$560K	Hold	2,600	–	–	0.03%	103
2023 Q4	$548K	Hold	2,600	–	–	0.04%	108
2023 Q3	$521K	Sell	2,600 -73,000	-97%	-$14.5M	0.04%	111
2023 Q2	$14M	Buy	+75,600	New	+$14M	0.99%	46
2017 Q3	–	Sell	-144,000	Closed	-$18M	–	120
2017 Q2	$18M	Hold	144,000	–	–	1.58%	21
2017 Q1	$17.1M	Hold	144,000	–	–	1.56%	24
2016 Q4	$16.6M	Hold	144,000	–	–	1.53%	27
2016 Q3	$15.1M	Buy	144,000 +12,800	+10%	+$1.34M	1.51%	32
2016 Q2	$12.8M	Hold	131,200	–	–	1.45%	33
2016 Q1	$12.6M	Buy	131,200 +1,700	+1%	+$155K	1.53%	31
2015 Q4	$11.7M	Hold	129,500	–	–	1.55%	28
2015 Q3	$12M	Hold	129,500	–	–	1.73%	25
2015 Q2	$12.1M	Hold	129,500	–	–	1.59%	26
2015 Q1	$12.3M	Buy	129,500 +25,100	+24%	+$2.33M	1.6%	26
2014 Q4	$9.26M	Buy	+104,400	New	+$8.85M	1.77%	22
2014 Q2	–	Sell	-28,700	Closed	-$2.12M	–	224
2014 Q1	$2.12M	Hold	28,700	–	–	0.83%	58
2013 Q4	$2.25M	Buy	+28,700	New	+$2.25M	0.77%	54

Other funds holding CME

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Payden & Rygel's CME Position: Q4 2024 in Review

Payden & Rygel sold out of CME Group (CME) in Q4 2024, closing a stake of 2,600 shares — an estimated $574K sold.

Payden & Rygel first reported a position in CME in Q4 2013 and held it in 19 quarters. The position peaked at $18M in Q2 2017. 1,500 funds tracked by Wall St. Rank hold CME as of Q4 2024.

Payden & Rygel reported no remaining CME Group position as of Q4 2024 after selling out during the quarter.
Payden & Rygel sold 2,600 CME Group shares in Q4 2024, an estimated $574K.
Payden & Rygel first reported a position in CME Group in Q4 2013 and held it in 19 quarters.
Payden & Rygel's CME Group position peaked at $18M in Q2 2017.
1,500 funds tracked by Wall St. Rank held CME Group as of Q4 2024.

Based on Payden & Rygel's 13F filing for Q4 2024, filed 13 Feb 2025.